{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T11:16:47Z","timestamp":1777979807568,"version":"3.51.4"},"reference-count":76,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Philadelphia-negative myeloproliferative neoplasms (MPNs), encompassing polycythemia vera, essential thrombocythemia, and primary myelofibrosis, represent a group of chronic clonal hematopoietic disorders characterized by excessive proliferation of myeloid lineages and with a propensity for arterial and venous thrombosis. These disorders provide a unique human model of inflammation-driven, clone-mediated vascular disease with mechanistic insights highly relevant to cardiovascular medicine. The interplay of elevated hematocrit, leukocytosis, activated platelets, neutrophil extracellular traps, endothelial dysfunction, and chronic cytokine elevation creates a multifaceted prothrombotic state. Randomized evidence, such as the CYTO-PV (cytoreductive therapy in polycythemia vera) trial, demonstrates that correcting hematocrit meaningfully reduces major cardiovascular and thrombotic events. Discoveries like Janus Kinase 2 valine-to phenylalanine substitution on position 617-mutated clones, altered platelet biology, and NETosis inform evolving concepts in coronary artery disease, microvascular ischemia, and inflammatory thrombosis. This review synthesizes thrombosis biology in MPNs with actionable implications for cardiologists. Key lessons include the importance of clonal hematopoiesis as a cardiovascular risk factor, the role of inflammation and hematologic dysregulation in accelerating atherothrombosis, and the therapeutic relevance of antiplatelet optimization, hematocrit control, cytoreductive therapy, and anti-inflammatory interventions. The review also outlines diagnostic situations in cardiology where MPNs should be suspected, proposes opportunities for improved risk stratification, and identifies research priorities bridging the 2 specialties.<\/jats:p>","DOI":"10.1097\/crd.0000000000001285","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:00:55Z","timestamp":1777561255000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Myeloproliferative Neoplasms, Clonal Thrombosis, and Vascular Disease: Can Cardiology Learn from Hematology?"],"prefix":"10.1097","author":[{"given":"Jatin","family":"Thukral","sequence":"first","affiliation":[{"name":"Departmnt of Internal Medicine, New York Medical College\/Landmark Medical Center, Woonsocket, RI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sehajnoor Kaur","family":"Khangurra","sequence":"additional","affiliation":[{"name":"Department of Medicine, Gian Sagar Medical College and Hospital, Ramnagar, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manav","family":"Ghaie","sequence":"additional","affiliation":[{"name":"Departmnt of Internal Medicine, New York Medical College\/Landmark Medical Center, Woonsocket, RI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maneet","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Medicine, Government Medical College, Patiala, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pyush","family":"Moudgil","sequence":"additional","affiliation":[{"name":"Department of Medicine, Gian Sagar Medical College and Hospital, Ramnagar, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riya","family":"Shah","sequence":"additional","affiliation":[{"name":"Departmnt of Internal Medicine, New York Medical College\/Landmark Medical Center, Woonsocket, RI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harbir","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Medicine, Internal Medicine, Hamilton Medical Center, Dalton, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Thukral","sequence":"additional","affiliation":[{"name":"Department of Occupational Therapy, Pt. Deendayal Upadhyaya National Institute for Persons With Physical Disabilities, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"R1-20260505","doi-asserted-by":"crossref","first-page":"100081","DOI":"10.1016\/j.tru.2021.100081","article-title":"Thrombosis in myeloproliferative neoplasms: a clinical and pathophysiological perspective.","volume":"5","author":"Kelliher","year":"2021","journal-title":"Thrombosis Update"},{"key":"R2-20260505","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"R3-20260505","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s11899-014-0228-z","article-title":"Epidemiology of MPN: what do we know?","volume":"9","author":"Anderson","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"key":"R4-20260505","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.thromres.2024.03.008","article-title":"Risk of thrombosis, hemorrhage and leukemic transformation in patients with myeloproliferative neoplasms: a nationwide longitudinal cohort study.","volume":"236","author":"Hur","year":"2024","journal-title":"Thromb Res"},{"key":"R5-20260505","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/jth.12265","article-title":"Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management.","volume":"11","author":"Casini","year":"2013","journal-title":"J Thromb Haemost"},{"key":"R6-20260505","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/1076029612453761","article-title":"Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.","volume":"19","author":"Sun","year":"2013","journal-title":"Clin Appl Thromb Hemost"},{"key":"R7-20260505","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease.","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"key":"R8-20260505","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/M17-0028","article-title":"Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study.","volume":"168","author":"Hultcrantz","year":"2018","journal-title":"Ann Intern Med"},{"key":"R9-20260505","doi-asserted-by":"crossref","first-page":"1382872","DOI":"10.3389\/fonc.2024.1382872","article-title":"Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectives.","volume":"14","author":"Breccia","year":"2024","journal-title":"Front Oncol"},{"key":"R10-20260505","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1053\/sonc.2002.33756","article-title":"The risk of thrombosis in essential thrombocythemia and polycythemia vera.","volume":"29","author":"Pearson","year":"2002","journal-title":"Semin Oncol"},{"key":"R11-20260505","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","article-title":"Thrombosis in primary myelofibrosis: incidence and risk factors.","volume":"115","author":"Barbui","year":"2010","journal-title":"Blood"},{"key":"R12-20260505","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.3390\/biomedicines13102543","article-title":"Clinical and molecular insights of arterial and venous thrombosis in myeloproliferative diseases\u2014case-based narrative review.","volume":"13","author":"Dr\u0103gan","year":"2025","journal-title":"Biomedicines"},{"key":"R13-20260505","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/2040620716680333","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease.","volume":"8","author":"How","year":"2017","journal-title":"Ther Adv Hematol"},{"key":"R14-20260505","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/ajh.26896","article-title":"Myeloproliferative neoplasms and splanchnic vein thrombosis: contemporary diagnostic and therapeutic strategies.","volume":"98","author":"Kiladjian","year":"2023","journal-title":"Am J Hematol"},{"key":"R15-20260505","doi-asserted-by":"crossref","DOI":"10.1097\/CRD.0000000000000735","article-title":"Safety and outcomes with direct oral anticoagulants versus vitamin-K antagonists in chronic thromboembolic pulmonary hypertension: a systematic review, meta-analysis, and meta-regression [published online ahead of print].","author":"Jain","year":"2024","journal-title":"Cardiol Rev"},{"key":"R16-20260505","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s11239-025-03100-7","article-title":"Comparison of safety and efficacy of ultrasound-accelerated thrombolysis vs. standard catheter-directed thrombolysis for the management of acute pulmonary embolism - a systematic review and meta-analysis.","volume":"58","author":"Passey","year":"2025","journal-title":"J Thromb Thrombolysis"},{"key":"R17-20260505","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12885-019-5387-9","article-title":"A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms.","volume":"19","author":"Rungjirajittranon","year":"2019","journal-title":"BMC Cancer"},{"key":"R18-20260505","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1001\/archinte.1989.00390010109013","article-title":"Erythromelalgia and myeloproliferative disorders.","volume":"149","author":"Kurzrock","year":"1989","journal-title":"Arch Intern Med"},{"key":"R19-20260505","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.blre.2014.12.002","article-title":"Mechanisms of thrombogenesis in polycythemia vera.","volume":"29","author":"Kroll","year":"2015","journal-title":"Blood Rev"},{"key":"R20-20260505","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1055\/s-2003-44552","article-title":"Hyperviscosity in polycythemia vera and other red cell abnormalities.","volume":"29","author":"Kwaan","year":"2003","journal-title":"Semin Thromb Hemost"},{"key":"R21-20260505","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis.","volume":"122","author":"Barbui","year":"2013","journal-title":"Blood"},{"key":"R22-20260505","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera.","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"key":"R23-20260505","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1007\/s11845-024-03776-5","article-title":"Association between JAK2V617F variable allele frequency and risk of thrombotic events in patients with myeloproliferative neoplasms.","volume":"193","author":"Brown","year":"2024","journal-title":"Ir J Med Sci"},{"key":"R24-20260505","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1182\/blood.2020008109","article-title":"The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms.","volume":"137","author":"Hasselbalch","year":"2021","journal-title":"Blood"},{"key":"R25-20260505","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1182\/blood-2013-10-531665","article-title":"Causal role for JAK2 V617F in thrombosis.","volume":"122","author":"Fleischman","year":"2013","journal-title":"Blood"},{"key":"R26-20260505","first-page":"169","article-title":"Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status.","volume":"91","author":"Arellano-Rodrigo","year":"2006","journal-title":"Haematologica"},{"key":"R27-20260505","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1186\/s12964-025-02358-x","article-title":"Activation of integrin signaling up-regulates pro-inflammatory cytokines in JAK2-V617F positive hematopoietic cells.","volume":"23","author":"Baldauf","year":"2025","journal-title":"Cell Commun Signal"},{"key":"R28-20260505","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3324\/haematol.2018.195321","article-title":"Vascular endothelial cell expression of JAK2V617F is sufficient to promote a pro-thrombotic state due to increased P-selectin expression.","volume":"104","author":"Guy","year":"2019","journal-title":"Haematologica"},{"key":"R29-20260505","doi-asserted-by":"crossref","first-page":"15880","DOI":"10.1073\/pnas.1005743107","article-title":"Extracellular DNA traps promote thrombosis.","volume":"107","author":"Fuchs","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R30-20260505","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1182\/bloodadvances.2020004061","article-title":"Increased levels of NETosis in myeloproliferative neoplasms are not linked to thrombotic events.","volume":"5","author":"Schmidt","year":"2021","journal-title":"Blood Adv"},{"key":"R31-20260505","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2016-06-722298","article-title":"In vitro activation of coagulation by human neutrophil DNA and histone proteins but not neutrophil extracellular traps.","volume":"129","author":"Noubouossie","year":"2017","journal-title":"Blood"},{"key":"R32-20260505","doi-asserted-by":"crossref","first-page":"100060","DOI":"10.1016\/j.rpth.2023.100060","article-title":"Platelet function studies in myeloproliferative neoplasms patients with calreticulin or JAK2V617F mutation.","volume":"7","author":"Guy","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"R33-20260505","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/ijlh.13754","article-title":"Correlation between leukocyte\u2010platelet aggregates and thrombosis in myeloproliferative neoplasms.","volume":"44","author":"\u0160efer","year":"2021","journal-title":"Int J Lab Hematology"},{"key":"R34-20260505","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1182\/blood.V112.11.5264.5264","article-title":"A retrospective literature review of erythromelalgia and myelorpoliferative disorders.","volume":"112","author":"Milani","year":"2008","journal-title":"Blood"},{"key":"R35-20260505","doi-asserted-by":"crossref","first-page":"102476","DOI":"10.1155\/2015\/102476","article-title":"MPNs as inflammatory diseases: the evidence, consequences, and perspectives.","volume":"2015","author":"Hasselbalch","year":"2015","journal-title":"Mediators Inflamm"},{"key":"R36-20260505","doi-asserted-by":"crossref","first-page":"683401","DOI":"10.3389\/fimmu.2021.683401","article-title":"Inflammatory pathophysiology as a contributor to myeloproliferative neoplasms.","volume":"12","author":"Fisher","year":"2021","journal-title":"Front Immunol"},{"key":"R37-20260505","doi-asserted-by":"crossref","first-page":"868934","DOI":"10.3389\/fcvm.2022.868934","article-title":"Inflammatory mediators in atherosclerotic vascular remodeling.","volume":"9","author":"Evans","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"R38-20260505","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/rheumato5030010","article-title":"Unequal burdens: exploring racial disparities in cardiovascular and SLE outcomes using national inpatient database 2016\u20132021.","volume":"5","author":"Shah","year":"2025","journal-title":"Rheumato"},{"key":"R39-20260505","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease.","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"R40-20260505","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jaccao.2022.04.002","article-title":"Cardiovascular disease in myeloproliferative neoplasms: JACC: cardiooncology state-of-the-art review.","volume":"4","author":"Leiva","year":"2022","journal-title":"JACC CardioOncol"},{"key":"R41-20260505","doi-asserted-by":"crossref","first-page":"113","DOI":"10.23736\/S0026-4806.25.09656-9","article-title":"Advancing heart failure management: a comprehensive review of current and emerging therapies for heart failure with preserved ejection failure.","volume":"116","author":"Agrawal","year":"2025","journal-title":"Minerva Med"},{"key":"R42-20260505","doi-asserted-by":"crossref","first-page":"S646","DOI":"10.1016\/S2152-2650(25)02087-7","article-title":"MPN-020: understanding the trend of myocardial infarction in patients with myeloproliferative neoplasms: an analysis of the National Inpatient Sample.","volume":"25","author":"Randhawa","year":"2025","journal-title":"Clin Lymph Myeloma Leukemia"},{"key":"R43-20260505","first-page":"93","article-title":"Outcomes of percutaneous coronary intervention in patients with inflammatory bowel disease: a propensity score-matched analysis.","volume":"42","author":"Jain","year":"2026","journal-title":"Can J Cardiol"},{"key":"R44-20260505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14796678.2026.2639403","article-title":"Post-myocardial infarction complications in patients with inflammatory bowel disease: a retrospective cohort study using the National Inpatient Sample (2016-2022) [published online ahead of print].","author":"Alkasabrah","year":"2026","journal-title":"Future Cardiol"},{"key":"R45-20260505","doi-asserted-by":"crossref","first-page":"10996","DOI":"10.1182\/blood-2022-171146","article-title":"Hematology referral, stroke recurrence and mortality among patients with first ischemic stroke and polycythemia or thrombocytosis.","volume":"140","author":"Lacerda","year":"2022","journal-title":"Blood"},{"key":"R46-20260505","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1055\/a-2482-3997","article-title":"Thrombosis at unusual sites: focus on myeloproliferative neoplasms and paroxysmal nocturnal hemoglobinuria.","volume":"45","author":"Koschmieder","year":"2025","journal-title":"Hamostaseologie"},{"key":"R47-20260505","doi-asserted-by":"crossref","first-page":"6828","DOI":"10.1097\/MS9.0000000000002603","article-title":"Sublingual hematoma as a rare complication of warfarin therapy in a patient with rheumatic heart disease: a case report.","volume":"86","author":"Idrees","year":"2024","journal-title":"Ann Med Surg (Lond)"},{"key":"R48-20260505","doi-asserted-by":"crossref","first-page":"100667","DOI":"10.1016\/j.jhepr.2022.100667","article-title":"Management of splanchnic vein thrombosis.","volume":"5","author":"Elkrief","year":"2023","journal-title":"JHEP Rep"},{"key":"R49-20260505","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41408-018-0101-8","article-title":"Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms.","volume":"8","author":"De Stefano","year":"2018","journal-title":"Blood Cancer J"},{"key":"R50-20260505","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/bloodadvances.2020003628","article-title":"A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms.","volume":"5","author":"Hamuly\u00e1k","year":"2021","journal-title":"Blood Adv"},{"key":"R51-20260505","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3390\/cancers12030573","article-title":"Ocular manifestations in patients with Philadelphia-negative myeloproliferative neoplasms.","volume":"12","author":"Liisborg","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R52-20260505","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0753-3322(96)89672-7","article-title":"Thrombotic and hemorrhagic complications in chronic myeloproliferative disorders.","volume":"50","author":"Sagripanti","year":"1996","journal-title":"Biomed Pharmacother"},{"key":"R53-20260505","doi-asserted-by":"crossref","first-page":"11287","DOI":"10.3390\/ijms241411287","article-title":"Coronary \"microvascular dysfunction\": evolving understanding of pathophysiology, clinical implications, and potential therapeutics.","volume":"24","author":"Kei","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R54-20260505","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an international prognostic score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis).","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"key":"R55-20260505","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/ajh.24293","article-title":"Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients.","volume":"91","author":"Haider","year":"2016","journal-title":"Am J Hematol"},{"key":"R56-20260505","doi-asserted-by":"crossref","first-page":"100335","DOI":"10.1016\/j.ajpc.2022.100335","article-title":"Atherosclerotic cardiovascular disease risk assessment: an American Society for Preventive Cardiology clinical practice statement.","volume":"10","author":"Wong","year":"2022","journal-title":"Am J Prev Cardiol"},{"key":"R57-20260505","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/eurheartj\/ehs314","article-title":"The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy.","volume":"34","author":"Coppens","year":"2013","journal-title":"Eur Heart J"},{"key":"R58-20260505","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1007\/s00277-024-05735-7","article-title":"Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice.","volume":"103","author":"Chojecki","year":"2024","journal-title":"Ann Hematol"},{"key":"R60-20260505","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera.","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"key":"R61-20260505","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/ajh.27002","article-title":"Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management.","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am J Hematol"},{"key":"R62-20260505","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.27216","article-title":"Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.","volume":"99","author":"Tefferi","year":"2024","journal-title":"Am J Hematol"},{"key":"R63-20260505","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/ajh.27418","article-title":"Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: the ARES trial.","volume":"99","author":"Rocca","year":"2024","journal-title":"Am J Hematol"},{"key":"R64-20260505","doi-asserted-by":"crossref","first-page":"2040620719870052","DOI":"10.1177\/2040620719870052","article-title":"Updates in the management of polycythemia vera and essential thrombocythemia.","volume":"10","author":"Bose","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"R65-20260505","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00277-018-3483-6","article-title":"High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation.","volume":"98","author":"Wille","year":"2019","journal-title":"Ann Hematol"},{"key":"R66-20260505","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1080\/14656566.2025.2610371","article-title":"Oral anticoagulation with versus without antiplatelet therapy in patients with stable coronary artery disease and an indication for anticoagulation: a meta-analysis with trial sequential analysis.","volume":"26","author":"Ibrahim","year":"2025","journal-title":"Expert Opin Pharmacother"},{"key":"R67-20260505","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1038\/s41375-021-01279-1","article-title":"Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients.","volume":"35","author":"Barbui","year":"2021","journal-title":"Leukemia"},{"key":"R68-20260505","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.amjcard.2026.01.006","article-title":"Effectiveness and safety of apixaban versus warfarin in atrial fibrillation patients with malignancy: a propensity-matched analysis.","volume":"264","author":"Agrawal","year":"2026","journal-title":"Am J Cardiol"},{"key":"R69-20260505","doi-asserted-by":"crossref","first-page":"612","DOI":"10.4143\/crt.2024.738","article-title":"The role of direct oral anticoagulants in managing myeloproliferative neoplasms patients.","volume":"57","author":"Lee","year":"2025","journal-title":"Cancer Res Treat"},{"key":"R70-20260505","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1038\/s41467-022-32928-3","article-title":"Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm.","volume":"13","author":"Rahman","year":"2022","journal-title":"Nat Commun"},{"key":"R71-20260505","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11899-019-00508-w","article-title":"Key role of inflammation in myeloproliferative neoplasms: instigator of disease initiation, progression. and symptoms.","volume":"14","author":"Mendez Luque","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"key":"R72-20260505","first-page":"101456","article-title":"Association between inflammatory bowel disease and atrial fibrillation: a systematic review and meta-analysis.","volume":"53","author":"Goyal","year":"2024","journal-title":"Int J Cardiol Heart Vasc"},{"key":"R73-20260505","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.yjmcc.2021.07.004","article-title":"Clonal hematopoiesis of indeterminate potential (CHIP): Linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease.","volume":"161","author":"Marnell","year":"2021","journal-title":"J Mol Cell Cardiol"},{"key":"R74-20260505","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1161\/CIRCRESAHA.118.311362","article-title":"NLRP3 inflammasome and the IL-1 pathway in atherosclerosis.","volume":"122","author":"Grebe","year":"2018","journal-title":"Circ Res"},{"key":"R75-20260505","doi-asserted-by":"crossref","first-page":"e70000","DOI":"10.1002\/jha2.70000","article-title":"Treatment of myeloproliferative neoplasms with janus kinase inhibitors: a meta-analysis of cardiovascular safety.","volume":"6","author":"Dunn","year":"2025","journal-title":"EJHaem"},{"key":"R76-20260505","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41569-025-01148-9","article-title":"Clonal haematopoiesis in cardiovascular disease: prognostic role and novel therapeutic target.","volume":"22","author":"Schuermans","year":"2025","journal-title":"Nat Rev Cardiol"},{"key":"R77-20260505","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00395-022-00969-w","article-title":"Clonal hematopoiesis and cardiovascular disease: deciphering interconnections.","volume":"117","author":"Stein","year":"2022","journal-title":"Basic Res Cardiol"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T11:01:52Z","timestamp":1777978912000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":76,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000001285","relation":{},"ISSN":["1061-5377","1538-4683"],"issn-type":[{"value":"1061-5377","type":"print"},{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]}}}